A Study to Evaluate 611 in Patients With Chronic Rhinosinusitis With Nasal Polyps

Inclusion Criteria: * Female and male patients aged ≥18 and ≤ 75 years at the time of screening. * Bilateral CRSwNP. * Bilateral NPS of ≥5 with a minimum score of 2 in each nasal cavity * Nasal Congestion Score of 2 at screening and a weekly average severity of 2 at time of randomization. * Patients whose bilateral sino-nasal polyposis remains inadequately controlled despite prior treatment with SCS anytime within the past 2 years; and/or had a medical contraindication/intolerance to SCS; and/or received nasal polyp surgery 6 months before signing the ICF. Exclusion Criteria: * Patients with other nasal diseases or symptoms. * Patients who are taking or have taken the following prohibited therapies as specified, e.g., systemic steroids within 4 weeks prior to screening, less than 3 months or 5 half-lives for biologic therapy prior to screening. * Patients who have active Hepatitis B, Hepatitis C or HIV infections as determined by positive results at Screening. * History of cancer. * Known or suspected history of immunosuppression. * Known with allergic or intolerant to mometasone furoate spray or 611/ placebo